Bioxytran Inc.

BIOXYTRAN, INC. (OTCQB: BIXT) is pleased to announce the initiation of coverage of its stock by Independent Research, a global equity research firm specializing in micro-cap and small-cap public companies.

Read the full press release:
https://tinyurl.com/9sjtm4d3

$BIXT
Bioxytran announced UGA confirmed the antiviral PHM23 was to be included in its grant submission to the U.S. Department of Agriculture’s (USDA) $100 million Highly Pathogenic Avian Influenza (HPAI) Poultry Innovation Grand Challenge.

READ FULL PRESS RELEASE ON OUR WEBSITE: 🔗 IN PROFILE
https://tinyurl.com/mwmjcj6d

$BIXT develops a GROUNDBREAKING TREATMENT to combat BIRD FLU in egg-laying chickens potentially saving billions.

READ FULL PRESS RELEASE!
👉🏻 https://tinyurl.com/5acjthnp

$BIXT CCO Mike Sheikh will be attending PMWC 2025 from February 5–7, 2025 to network with Big & Small Pharma for licensing & partnership opportunities.

Connect with on overcoming Immune Checkpoint Resistance in & the reality of Broad Spectrum Antivirals capable of defeating Quadremic outbreaks. [email protected]

Key speakers will be $NVDA Jensen Huang & Nobel Laureate Carolyn Bertozzi.